Join the Vocabria group to help and get support from people like you.
Vocabria News
Preexposure Prophylaxis Use for HIV Increased in Recent Years
MONDAY, Oct. 21, 2024 – Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 in the Journal of the American Medical ...
Long-Acting Cabotegravir Well Tolerated in Pregnant Women
THURSDAY, Aug. 8, 2024 – Long-acting injectable cabotegravir (CAB-LA) appears to be well tolerated in pregnant women, according to a study presented at AIDS 2024, the 25th International AIDS...
Long-Acting Early Viral Inhibition Described in Context of Long-Acting Injectable Cabotegravir
MONDAY, July 29, 2024 – In a research letter published online July 24 in the New England Journal of Medicine, the authors describe long-acting early viral inhibition (LEVI) among patients with acute...
FDA Approves Cabenuva (cabotegravir and rilpivirine) Long-Acting Injectable HIV Treatment and Vocabria (cabotegravir) Oral HIV Treatment
London, 21 January 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that ...